Patients receiving hemodialysis do not lose SARS-CoV-2 antibodies more rapidly than non-renal controls: a prospective cohort study.
Ekaterina V ParshinaAlexey B ZulkarnaevAlexey D TolkachAndrey V IvanovPavel N KislyyAbduzhappar E GaipovPublished in: Renal failure (2022)
Compared with non-renal adults, patients receiving HD maintain significant long-term humoral and cellular immune responses following natural COVID-19.